News & articles
FDA Approves MIMRYLO (Rusfertide), a Hepcidin-Mimetic Peptide for Polycythemia VeraThe FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.
- Ketone Esters Plus Semaglutide: Preclinical Data on Muscle Preservation Draws Attention
Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.
- ENDO 2026: GLP-1 and Multi-Agonist Peptides Dominate Chicago Readouts
ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.
- Matrixyl and Argireline Peptides Re-enter Mass-Market Anti-Wrinkle Pipelines
Classic Matrixyl and Argireline peptides return to mass-market anti-wrinkle launches in 2026.
- Cosmetic Buyers Adopt Research-Grade Release Criteria for Peptide Raw Materials
Cosmetic buyers tighten peptide release criteria; data integrity rises on 2026 audit agendas.
- ICPEWG Publishes Updated Guidance on Cosmetic Peptide Impurity Reporting
ICPEWG updates guidance on how cosmetic peptide impurities should be reported on COAs.